安德鲁·休伯曼 (Andrew Huberman) 的 Huberman Lab 播客节目重点讨论了氯胺酮，包括它在治疗抑郁症、自杀倾向和 PTSD (创伤后应激障碍) 方面的临床益处，其潜在的滥用风险，以及它在大脑中的作用机制。休伯曼解释说，氯胺酮是一种分离性麻醉剂，类似于 PCP (苯环利定)，它已经从主要被视为一种街头毒品，转变成为一种临床上使用的治疗方法。 他首先驳斥了抑郁症的单胺假说，该假说认为血清素、多巴胺或去甲肾上腺素的缺乏会导致抑郁症。 虽然增加这些单胺的药物可以为某些人提供缓解，但它们只对大约 40% 的抑郁症患者有效，并且常常伴随副作用。 这促使人们寻找替代疗法，例如氯胺酮。 休伯曼随后详细介绍了氯胺酮临床使用的历史。 抑郁症的动物模型，例如“习得性无助”模型，表明氯胺酮可以让动物为自己的生命抗争更长时间，暗示了抗抑郁作用。 这导致了在人类中的临床试验，该试验表明氯胺酮可以迅速缓解抑郁症，即使在难治性病例中也是如此。 它还显示出治疗双相情感障碍、PTSD、强迫症、焦虑症和物质成瘾的潜力。 然而，氯胺酮的快速作用与它的短暂效应相伴随，需要频繁给药。 这引发了人们对潜在滥用和成瘾的担忧。 研究已经探索了给药方案，例如每周两次，持续三周，这显示出抗抑郁效果具有一定的持久性。 这表明存在多种作用机制：立即缓解、短期缓解以及神经回路的长期变化。 休伯曼深入研究了氯胺酮的神经生物学机制，强调了神经可塑性，即大脑根据经验改变的能力。 他解释说，氯胺酮阻断了 NMDA 受体，这种受体对于许多形式的神经可塑性至关重要。 然而，氯胺酮的抗抑郁作用似乎是矛盾的，因为 NMDA 受体的阻断表面上会*降低*神经可塑性。 他通过描述两种主要的神经元类型来解释这个悖论：兴奋性神经元和抑制性神经元。 氯胺酮阻断抑制性神经元上的 NMDA 受体，减少它们对特定大脑回路中兴奋性神经元的抑制性输出。 这使得兴奋性神经元可以“爆发”出电活动，这是一种完美的模式，可以诱导与情绪、奖励和自我反思相关的神经回路的短期和长期变化。 爆发性放电导致 BDNF (脑源性神经营养因子) 的释放，这是一种对于所有形式的学习和记忆至关重要的分子。 BDNF 与其受体结合并触发一系列事件，包括将新的谷氨酸受体插入神经元，使它们对输入更加敏感。 在某些情况下，氯胺酮本身也可以模拟 BDNF 的效果。 他澄清说，虽然 NMDA 受体很重要，但氯胺酮也会影响阿片类通路，该通路在疼痛和情绪中起着重要作用。 氯胺酮代谢成羟基去甲氯胺酮 (HNK)，选择性地激活阿片类系统。 研究表明，用纳曲酮阻断阿片类系统会减弱氯胺酮的抗抑郁作用，这表明阿片类系统是氯胺酮临床益处的一个关键贡献者。 休伯曼强调了将氯胺酮的即时主观效应与其长期临床益处区分开来的重要性。 患者在氯胺酮影响下的体验会引发一系列事件，最终导致神经回路和神经递质系统的变化。 休伯曼讨论了氯胺酮改变的特定大脑回路，包括减弱失望回路 (缰核) 和奖励回路之间的连接。 氯胺酮可以改善额叶皮层和奖励通路之间的连接，这使得人们对自己的成就以及如何从自己的行为中获得结果更加敏感。 然后，他讨论了氯胺酮的主观效应（例如分离感）是如何由皮层和皮层下大脑网络解耦以及独特脑电波模式的出现而产生的。 接着他提到氯胺酮的不同给药方式，其中注射型氯胺酮具有最高的生物利用度，其次是舌下给药，最后是口服。 他还将 "K-hole" 定义为服用娱乐性氯胺酮剂量，其剂量足以引起完全麻醉。 他警告说，氯胺酮的剂量和敏感性因人而异，并且受到给药途径的影响。 他还讨论了各种 SR (缓释) 版本的氯胺酮，其中 SR 组合形式在缓解抑郁症症状方面更有效。 他最后表示，截至目前，没有已发表的临床证据支持氯胺酮微剂量给药能够有效缓解抑郁症。 最后，休伯曼强调，抗抑郁行为，例如寻求社会参与和规律睡眠，对于加强通过氯胺酮治疗获得的积极变化至关重要。

Andrew Huberman's Huberman Lab podcast episode focuses on ketamine, its clinical benefits for depression, suicidality, and PTSD, its potential for abuse, and its mechanisms of action in the brain. Huberman explains that ketamine is a dissociative anesthetic, similar to PCP, that has transitioned from being primarily viewed as a street drug to a clinically utilized treatment. He begins by debunking the monoamine hypothesis of depression, which posits that deficiencies in serotonin, dopamine, or norepinephrine cause depression. While drugs that increase these monoamines can provide relief for some, they only work in about 40% of depressed individuals and often come with side effects. This led to the search for alternative treatments, like ketamine. Huberman then details the history of ketamine's clinical use. Animal models of depression, such as the "learned helplessness" model, revealed that ketamine allowed animals to fight for their lives longer, suggesting antidepressant effects. This led to clinical trials in humans, which demonstrated that ketamine could provide rapid relief from depression, even in treatment-resistant cases. It also showed promise for bipolar depression, PTSD, OCD, anxiety, and substance addiction. However, ketamine's rapid-acting nature is coupled with its short-lived effects, requiring frequent dosing. This raises concerns about potential abuse and addiction. Studies have explored dosing regimens such as twice a week for three weeks, which showed some durability in antidepressant effects. This suggests multiple mechanisms of action: immediate relief, short-term relief, and long-term changes in neural circuitry. Huberman delves into the neurobiological mechanisms of ketamine, emphasizing neuroplasticity, the brain's ability to change in response to experience. He explains that ketamine blocks the NMDA receptor, a crucial receptor for many forms of neuroplasticity. However, ketamine's antidepressant effects appear paradoxical, since NMDA receptor blockage would ostensibly *reduce* neuroplasticity. He explains this paradox by describing the two major types of neurons: excitatory and inhibitory. Ketamine blocks NMDA receptors on inhibitory neurons, reducing their inhibitory output onto excitatory neurons in specific brain circuits. This allows excitatory neurons to "burst" with electrical activity, a perfect pattern to induce both short- and long-term changes in neural circuits associated with mood, reward, and self-reflection. The burst firing leads to the release of BDNF (Brain-Derived Neurotrophic Factor), a molecule critical for all forms of learning and memory. BDNF binds to its receptors and triggers a cascade of events, including the insertion of new glutamate receptors on neurons, making them more sensitive to input. In some cases, ketamine itself can also mimic the effects of BDNF. He clarifies that while the NMDA receptor is important, ketamine also impacts the opioid pathway, which plays a major role in pain and mood. Ketamine metabolizes into hydroxynorketamine (HNK), which selectively activates the opioid system. Studies have shown that blocking the opioid system with naltrexone attenuates the antidepressant effects of ketamine, suggesting the opioid system as a key contributor to ketamine's clinical benefits. Huberman underscores the importance of separating the immediate subjective effects of ketamine from its long-term clinical benefits. The patient's experience while under the influence of ketamine sets off a series of events that ultimately lead to changes in neural circuitry and neurotransmitter systems. Huberman discusses the specific brain circuits altered by ketamine, including the weakening of the connection between the disappointment circuit (habenula) and the reward circuitry. Ketamine can improve connectivity between the frontal cortex and the reward pathways, which makes people more sensitive to their achievements and to how to get results from their behaviors. He then discusses how the subjective effects of ketamine, such as dissociation, arise from an uncoupling of cortical and subcortical brain networks, and the emergence of unique brain wave patterns. He then addresses the different delivery methods of ketamine, with injectable ketamine having higher bioavailability, then sublingual and then oral routes. He then defines a "K-hole" as taking a recreational ketamine dose high enough to cause full anesthesia. He cautions that ketamine dosage and sensitivity vary greatly among individuals and are influenced by the route of administration. He also discusses various SR versions of ketamine, with the SR combined form being more potent at relieving depression symptoms. He ends by stating that as of today, there is zero published clinical evidence to support the effectiveness of microdosing ketamine to relieve depression. Finally, Huberman emphasizes that antidepressant behaviors, such as seeking social engagement, and regular sleep, are essential to reinforcing positive changes achieved through ketamine treatment.